GlassScriptPhysician profile
Ashil Jitendra Gosalia
NPI 1477846525
$2,804.01
in general payments reported to CMS, 2019-2025
22 companies · $523 in 2025
The $523 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $780 · 2023: $957 · 2024: $544 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,023.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $890.84 | 2022-2025 | |
| Braintree Laboratories, INC. | $238.50 | 2022-2025 | Suflave, Sutab |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.37 | 2022-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $182.37 | 2022-2024 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $153.06 | 2022-2024 | Entyvio |
| Celgene Corporation | $141.05 | 2022-2023 | Zeposia |
| Lucid Diagnostics INC. | $140.37 | 2025 | |
| Mallinckrodt Hospital Products INC. | $136.49 | 2022-2024 | Terlivaz |
| Genzyme Corporation | $100.21 | 2022-2023 | |
| Olympus America INC. | $98.86 | 2023 | Evis Exera III Gastrointestinal Videoscope |
| Phathom Pharmaceuticals, INC. | $96.45 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $77.46 | 2022-2024 | Talicia, Aemcolo |
| Regeneron Healthcare Solutions, INC. | $70.10 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $56.53 | 2023 | Rebyota |
| Qol Medical, LLC | $37.75 | 2025 | Sucraid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $31.74 | 2024 | Resmetirom |
| Ipsen Biopharmaceuticals, INC | $29.13 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $25.49 | 2024 | |
| Exact Sciences Corporation | $24.87 | 2023 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $24.62 | 2022 | |
| Coloplast Corp | $23.76 | 2024 | |
| Enterra Medical, INC. | $21.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashil Gosalia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.